When Trump had Covid-19 last month, he received Regeneron's experimental antibody treatment, which is still in large-scale clinical trials but has been available for compassionate use - something the FDA has to approve on an individual basis, as it did for the President. Drugmaker Regeneron came up with REGEN-COV2 (a combination of two lab-made antibodies) that helped in reduction of COVID-19 infected patients needing hospitalizations or emergency room visits.
"Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system", said Stephen Hahn, commissioner of the Food and Drug Administration. REGN-COV2 was one of the treatments President Donald Trump received after he was admitted to the hospital with Covid-19. A similar antibody therapy made by Eli Lilly & Co. received emergency clearance from the FDA on November 9.
The treatment is part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies created by the human body to fight infections.
They work by binding to a surface protein of the SARS-CoV-2 virus and stopping it from invading human cells.
Advertisement. Scroll to continue reading.
The FDA allowed its use in adults and children 12 and over who weigh at least 88 pounds (40 kilograms) and who are at high risk of severe illness from COVID-19 because of age or certain other medical conditions.
This compared to nine percent in placebo-treated patients. Patients with other conditions like diabetes, cardiovascular disease or chronic kidney disease also qualify for the drug.
These will be available to United States patients at no out-of-pocket cost under the terms of a usa government program.
Initial supplies will likely be vastly outstripped by demand as the USA has surged past 10 million reported cases, with the country facing what health experts say will be a dark winter due uncontrolled spread of the virus.
As TheBlaze reported, Carson contracted COVID-19 about two weeks ago.
Regeneron has received more than $450 million from the U.S. government for its Covid-19 drug development efforts under Operation Warp Speed.
The emergency authorisation for Regeneron's drug is, however, limited in scope.